Anebulo Pharmaceuticals (NASDAQ:ANEB) Announces Earnings Results

Anebulo Pharmaceuticals (NASDAQ:ANEB) issued its quarterly earnings results on Tuesday. The company reported ($0.04) earnings per share for the quarter, Zacks reports.

Anebulo Pharmaceuticals Stock Performance

NASDAQ ANEB opened at $0.98 on Wednesday. Anebulo Pharmaceuticals has a one year low of $0.80 and a one year high of $3.08. The business has a fifty day moving average price of $1.21 and a 200 day moving average price of $1.40. The company has a market cap of $40.06 million, a P/E ratio of -3.48 and a beta of -1.12.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.